Cipher Pharmaceuticals (TSE:CPH) Stock Price Breaks Below 50-Day Moving Average – What’s Next?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of C$15.03 and traded as low as C$13.51. Cipher Pharmaceuticals shares last traded at C$13.69, with a volume of 13,619 shares trading hands.

Cipher Pharmaceuticals Stock Performance

The company has a market cap of C$346.59 million, a price-to-earnings ratio of 12.19 and a beta of 1.05. The company has a quick ratio of 2.67, a current ratio of 1.59 and a debt-to-equity ratio of 0.27. The company’s 50-day moving average is C$14.97 and its 200 day moving average is C$16.47.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported C$0.21 earnings per share for the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%. The business had revenue of C$17.14 million during the quarter. Research analysts predict that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current year.

Insider Transactions at Cipher Pharmaceuticals

In other Cipher Pharmaceuticals news, Director Craig Mull acquired 20,000 shares of the company’s stock in a transaction on Friday, September 18th. The shares were bought at an average cost of C$14.16 per share, with a total value of C$283,200.00. Following the completion of the acquisition, the director owned 1,009,953 shares in the company, valued at approximately C$14,300,934.48. This trade represents a 2.02% increase in their ownership of the stock. Corporate insiders own 42.00% of the company’s stock.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.